Emergent executes Letter of Intent with Regen Biowellness, Inc.; Former L'Oréal President Jim Morrison to join Emergents Management Team
Emergent Health Corp. (OTC PINK:EMGE) announced a Letter of Intent to acquire Regen Biowellness, Inc., expanding its portfolio in the plant-based and regenerative medical fields. Jim Morrison, former President of L'Oréal, will join Emergent's management team. The deal aims to integrate Regen's patent-protected products including Immuniain™ and various cannabinoid compositions into Emergent's offerings. The acquisition is expected to close by mid-to-end July 2022, following the dismissal of Regen's bankruptcy petition.
- Acquisition of Regen Biowellness will diversify Emergent's product offerings in health and wellness.
- Presence of Jim Morrison, a high-profile leader from L'Oréal, potentially enhances brand strategy and market penetration.
- Regen is currently undergoing bankruptcy proceedings, posing risks to the acquisition process.
HAUPPAUGE, NY / ACCESSWIRE / July 6, 2022 / Emergent Health Corp. ("Emergent") (OTC PINK:EMGE) announces it has executed a Letter of Intent to acquire Regen Biowellness, Inc., f/k/a Availa Bio, Inc. ("Regen"), a distributor of various products in the plant-based and regenerative medical fields.
Upon the completion of the transaction, Jim Morrison, President and CEO of Regen will join the management team of Emergent. Mr. Morrison is a legend in the personal care industry, most notably as President of L'Oréal. While at L'Oréal, Morrison oversaw growth that averaged more than
Business Week Magazine previously wrote: "Over the last two decades, Mr. Morrison has had a profound impact on the American Beauty Industry. In the industry's history no other executive has had the level of financial responsibility or breadth of organizational experience as Jim. His devotion to, and success within the American Beauty Industry is unmatched."
Regen Biowellness products include:
Product with Issued Patents
Immuniain TM (Immune Booster) - Irreversibly-inactivated pepsinogen fragments for modulating immune function (Immune Booster- FDA Cleared)
ImmunaZin contains an FDA approved New Dietary Ingredient (NDI), and the NDI # is 1140
Patent No. US 8,309,072; Patent Issued: November 13, 2012
Pending Patent Applications
Veterinary Cannabinoid and Menthol Compositions and Methods
Application No. 16/419,392; International Application PCT/US2019/048695
Cannabinoid and Menthol Compositions and Methods
US Application No. 16/419,336; International Application PCT/US2019/048691
Thin Film Toothpaste Strip, European Application
Product Name: KidzStrips ®
Thin Film Toothpaste Strip, Eurasian Application
Product Name: KidzStrips ®
Fertilizer
Product Name: HydroSoil ®, Water retaining Hemp enhanced fertilizer, water plant once every two weeks
Other Products
IcyEase
Adhesive Ice Pack for muscle/joint pain to cool surface and address pain.
Patent-pending, FDA pain claim in progress. IcyEase contains menthol, menthol is an approved pain relief ingredient in the FDA's monograph for topical pain relief
Micro Voltage Trans Derm C
patent application in progress for pain with unique and superior absorbing features due to wearer's movement generated Micro Voltage
Silverpro - our only FDA approved medical device for the treatment of pain. Revolutionary technology combining genuine silver yarn with low-static carbon fibers, to create the world's most advanced-compression pain relief fabric
The acquisition of Regen, along with the human and pet related products already in the Emergent family, through its subsidiaries Emergent OTC and Emergent Medical Foods for humans, as well as Pharmazu's products for pets, plans to create a complete human and pet portfolio of products. With the previously announced acquisition of Fusion Pharmacy on June 29th 2022, Emergent intends to be a major participant in the field of OTC human and pet products.
Regen is currently awaiting its Bankruptcy Petition to be dismissed pursuant to a Settlement Agreement. Once dismissed by the Bankruptcy Court, the closing of the transaction, pending approvals, is anticipated to be mid-to-end July 2022. Emergent is very excited for the opportunity to take over Regen to market and distribute its incredible line of products.
James W. Zimbler, CEO of Emergent stated, "Emergent is embarking on a course to expand its health and wellness, biologic medical offering for both people and pets. When the transactions are closed, the added entities, along with our current offerings, including pet meds offered through PharmaZu, will provide an enormous variety of products."
Jim Morrison, President and CEO of Regen Biowellness stated, "The new Emergent Health is positioned to be a transformational company in the "family health and wellness" space. From ‘PharmaZu' for your pets to the most serious forms of regenerative wellness. The company has unlimited potential."
ABOUT EMERGENT HEALTH CORPORATION
Emergent Health Corp. is developing a product line in the field of Regenerative Medicine and improved neutraceuticals and phytonutritionals available to the general public without a prescription.... Its products comprise ingestibles as well as topicals for the whole family. The company distributes its products online and through Content Based Shopping using Influencers to position products in their produced content throughout the United States and Internationally. PharmaZu its newly acquired subsidiary, is a pure play, e-commerce products and service provider focused on The Pet Community, Pet Pharmacy and Wellness using Influencers and their content, including the pet pharmacy, vet telehealth and pet wellness businesses. Emergent does not claim any of its products are approved by the FDA to diagnose, treat, cure or prevent any disease.
Before using any products, you should always consult with your Veterinarian and Family Doctor.
SAFE HARBOR STATEMENT
This press release contains forward-looking statements that can be identified by terminology such as "believes," "expects," "potential," "plans," "suggests," "may," "should," "could," "intends," or similar expressions. Many forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results implied by such statements. These factors include, but are not limited to, our ability to continue to enhance our products and systems to address industry changes, our ability to expand our customer base and retain existing customers, our ability to effectively compete in our market segment, the lack of public information on our company, our ability to raise sufficient capital to fund our business, operations, our ability to continue as a going concern, and a limited public market for our common stock, among other risks. Many factors are difficult to predict accurately and are generally beyond the company's control. Forward-looking statements speak only as to the date they are made, and we do not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
FOR MORE INFORMATION, PLEASE CONTACT:
James Zimbler, CEO
jzimbler@emergenthealthcompany.com
631-806-1420
https://emergenthealthcompany.com/
SOURCE: Emergent Health Corp.
View source version on accesswire.com:
https://www.accesswire.com/707695/Emergent-executes-Letter-of-Intent-with-Regen-Biowellness-Inc-Former-LOral-President-Jim-Morrison-to-join-Emergents-Management-Team
FAQ
What is the significance of Emergent's acquisition of Regen Biowellness (EMGE)?
Who will join Emergent's management team after the acquisition of Regen (EMGE)?
When is the closing date expected for the acquisition of Regen by Emergent (EMGE)?
What are the products included in Regen's portfolio after the acquisition by Emergent (EMGE)?
